Table 3.
Risk of CIN3+ and CIN2+ among HPV-positive women with NILM cytology by HPV genotype at baseline screening until regular follow-up of 21 months.
| CIN3+ | CIN2+ | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total | N (cases) | Risk | 95%CI | N (cases) | Risk | 95%CI | |||
| Baseline HPV Result | |||||||||
| HPV-positivea | 1278 | 102 | 8.0 | 6.6 | 9.6 | 154 | 12.1 | 10.4 | 14.0 |
| HPV16 | 201 | 40 | 19.9 | 15.0 | 26.1 | 49 | 24.4 | 19.0 | 30.9 |
| HPV18 | 74 | 8 | 10.8 | 5.6 | 20.5 | 12 | 16.2 | 9.6 | 26.8 |
| Other high-risk HPVb | 981 | 54 | 5.5 | 4.2 | 7.1 | 92 | 9.4 | 7.7 | 11.4 |
CIN cervical intraepithelial neoplasia, CI confidence interval, NILM negative for intraepithelial lesion or malignancy.
aIncludes all HPV-positive persons with NILM cytology, including 22 not HPV genotyped.
bIncludes HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.